目的:探讨KRAS在肝细胞肝癌(HCC)中的表达特征及其与临床特征、免疫检查点和肿瘤突变负荷(TMB)的相关性。方法:利用TCGA数据库中374例HCC患者和50例正常对照的RNA-seq数据,分析KRAS的差异表达,并结合临床资料进行临床特征相关性分析;同...目的:探讨KRAS在肝细胞肝癌(HCC)中的表达特征及其与临床特征、免疫检查点和肿瘤突变负荷(TMB)的相关性。方法:利用TCGA数据库中374例HCC患者和50例正常对照的RNA-seq数据,分析KRAS的差异表达,并结合临床资料进行临床特征相关性分析;同时评估KRAS与免疫检查点基因的相关性及其与TMB的关系。结果:KRAS在HCC组织中显著高表达(P<0.001),其表达水平与年龄(P=0.022)、性别(P=0.017)和肿瘤分期(Stage 1 vs Stage 3,P=0.0033)显著相关;发现KRAS与33个免疫检查点基因存在显著相关性,其中与NRP1(r=0.551)、CD276(r=0.499)和TNFSF4(r=0.464)的相关性最强;此外,KRAS表达与TMB呈现微弱但显著的负相关(r=-0.11,P=0.037)。结论:KRAS在HCC中的异常表达及其与免疫检查点的显著相关性提示其可能通过调节肿瘤免疫微环境参与HCC的发生发展,为HCC的诊疗提供新的潜在靶点。展开更多
本研究基于TCGA数据库,采用生物信息学方法构建了肾透明细胞癌(ccRCC)的蛋白质预后模型,并探讨了其免疫浸润特征。通过蛋白组学分析筛选出8个关键蛋白质,建立了预测患者预后的模型,并通过生存分析、ROC曲线及风险曲线对模型的稳定性与...本研究基于TCGA数据库,采用生物信息学方法构建了肾透明细胞癌(ccRCC)的蛋白质预后模型,并探讨了其免疫浸润特征。通过蛋白组学分析筛选出8个关键蛋白质,建立了预测患者预后的模型,并通过生存分析、ROC曲线及风险曲线对模型的稳定性与准确性进行了验证,进一步应用列线图预测患者的生存期,为临床决策提供辅助工具。此外,分析了模型中蛋白质间以及模型蛋白与其他关键蛋白之间的共表达关系,揭示了它们在ccRCC中的潜在作用。研究还深入探讨了免疫细胞的表达情况,并比较了高风险组与低风险组的免疫应答差异。结果显示,免疫细胞的浸润与患者预后密切相关,高风险组显示出较低的免疫应答,提示免疫微环境可能在肾透明细胞癌的进展中起重要作用。本研究为肾透明细胞癌的个体化治疗提供了新的预后模型,并为免疫治疗的相关研究奠定了基础。Based on the TCGA database, this study constructed a protein prognostic model for renal clear cell carcinoma using bioinformatics methods and explored its immune infiltration characteristics. Eight key proteins were identified through proteomic analysis, and a model for predicting patient prognosis was established. The stability and accuracy of the model were validated through survival analysis, ROC curve, and risk curve. Furthermore, column charts were used to predict patient survival, providing an auxiliary tool for clinical decision-making. In addition, the co expression relationships between proteins in the model and between model proteins and other key proteins were analyzed, revealing their potential roles in ccRCC. The study also delved into the expression of immune cells and compared the differences in immune responses between high-risk and low-risk groups. The results showed that the infiltration of immune cells is closely related to the prognosis of patients, and the high-risk group showed a lower immune response, suggesting that the immune microenvironment may play an important role in the progression of renal clear cell carcinoma. This study provides a new prognostic model for individualized treatment of renal clear cell carcinoma and lays the foundation for related research on immunotherapy.展开更多
文摘目的:探讨KRAS在肝细胞肝癌(HCC)中的表达特征及其与临床特征、免疫检查点和肿瘤突变负荷(TMB)的相关性。方法:利用TCGA数据库中374例HCC患者和50例正常对照的RNA-seq数据,分析KRAS的差异表达,并结合临床资料进行临床特征相关性分析;同时评估KRAS与免疫检查点基因的相关性及其与TMB的关系。结果:KRAS在HCC组织中显著高表达(P<0.001),其表达水平与年龄(P=0.022)、性别(P=0.017)和肿瘤分期(Stage 1 vs Stage 3,P=0.0033)显著相关;发现KRAS与33个免疫检查点基因存在显著相关性,其中与NRP1(r=0.551)、CD276(r=0.499)和TNFSF4(r=0.464)的相关性最强;此外,KRAS表达与TMB呈现微弱但显著的负相关(r=-0.11,P=0.037)。结论:KRAS在HCC中的异常表达及其与免疫检查点的显著相关性提示其可能通过调节肿瘤免疫微环境参与HCC的发生发展,为HCC的诊疗提供新的潜在靶点。
文摘本研究基于TCGA数据库,采用生物信息学方法构建了肾透明细胞癌(ccRCC)的蛋白质预后模型,并探讨了其免疫浸润特征。通过蛋白组学分析筛选出8个关键蛋白质,建立了预测患者预后的模型,并通过生存分析、ROC曲线及风险曲线对模型的稳定性与准确性进行了验证,进一步应用列线图预测患者的生存期,为临床决策提供辅助工具。此外,分析了模型中蛋白质间以及模型蛋白与其他关键蛋白之间的共表达关系,揭示了它们在ccRCC中的潜在作用。研究还深入探讨了免疫细胞的表达情况,并比较了高风险组与低风险组的免疫应答差异。结果显示,免疫细胞的浸润与患者预后密切相关,高风险组显示出较低的免疫应答,提示免疫微环境可能在肾透明细胞癌的进展中起重要作用。本研究为肾透明细胞癌的个体化治疗提供了新的预后模型,并为免疫治疗的相关研究奠定了基础。Based on the TCGA database, this study constructed a protein prognostic model for renal clear cell carcinoma using bioinformatics methods and explored its immune infiltration characteristics. Eight key proteins were identified through proteomic analysis, and a model for predicting patient prognosis was established. The stability and accuracy of the model were validated through survival analysis, ROC curve, and risk curve. Furthermore, column charts were used to predict patient survival, providing an auxiliary tool for clinical decision-making. In addition, the co expression relationships between proteins in the model and between model proteins and other key proteins were analyzed, revealing their potential roles in ccRCC. The study also delved into the expression of immune cells and compared the differences in immune responses between high-risk and low-risk groups. The results showed that the infiltration of immune cells is closely related to the prognosis of patients, and the high-risk group showed a lower immune response, suggesting that the immune microenvironment may play an important role in the progression of renal clear cell carcinoma. This study provides a new prognostic model for individualized treatment of renal clear cell carcinoma and lays the foundation for related research on immunotherapy.
